936 Results

People

  1. Tap
    Tap
  2. D'Angelo
    D'Angelo
  3. Gounder
    Gounder
  4. Chi
    Chi
  5. Dickson
    Dickson
  6. Antonescu
    Antonescu
  7. Keohan
    Keohan
  8. Singer
    Singer
  9. Kelly
    Kelly
  10. Qin
    Qin

Groups

  1. Department of Medicine (936)
  2. Sarcoma Service (936)
  3. Solid Tumor Oncology Division (936)
  4. GSK Faculty (336)
  5. Tow Center for Developmental Oncology (TCDO) (304)
  6. Hematologic Malignancies, Division of (289)
  7. Department of Pathology and Laboratory Medicine (237)
  8. Human Oncology and Pathogenesis Program (232)
  9. Surgery (199)
  10. Sarcoma Surgeons (142)
  1. "Sarcoma Service"
Formats
  1. Journal Article (444)
  2. Meeting Abstract (429)
  3. Review (26)
  4. Editorial (8)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (936)
  2. Sarcoma Service (936)
  3. Solid Tumor Oncology Division (936)
  4. GSK Faculty (336)
  5. Tow Center for Developmental Oncology (TCDO) (304)
  6. Hematologic Malignancies, Division of (289)

More Groups

People
  1. William Tap (372)
  2. Sandra D'Angelo (252)
  3. Mrinal Gounder (228)
  4. Ping Chi (172)
  5. Mark Dickson (169)
  6. Cristina Antonescu (135)

More People

Years
  1. 2025 (27)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (272)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (60)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (25)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (286)
  2. American Association for Cancer Research (107)
  3. Oxford University Press (91)
  4. Elsevier Inc. (59)
  5. Nature Publishing Group (41)
  6. Springer (40)

More Publishers

Results (936)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vascular endothelial growth factor and programmed cell death-1 inhibition in bone sarcomas
    Editorial

    Reinhorn, D.; D’Angelo, S. P.
    Cancer (2025)

    Fulltext@MSK | Save
  • A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
    Journal Article

    Desai, J.; Wagner, A. J.; Carrasco Garcia, I.; Cesari, M.; Gordon, M.; Lin, C. C.; Papai, Z.; Ryan, C. W.; Tap, W. D.; Trent, J. C.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Loss of KMT2C or KMT2D primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters
    Journal Article

    Wang, N.; Pachai, M. R.; Li, D.; Lee, C. J.; Warda, S.; Khudoynazarova, M. N.; Cho, W. H.; Xie, G.; Shah, S. R.; Yao, L.; more...
    Nature Genetics (2025)

    Fulltext@MSK | Save
  • MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: A phase I trial
    Journal Article

    Gounder, M.; Johnson, M.; Heist, R. S.; Shapiro, G. I.; Postel-Vinay, S.; Wilson, F. H.; Garralda, E.; Wulf, G.; Almon, C.; Nabhan, S.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • Next-generation sequencing for HLA genotype screening and matching to HLA-restricted therapies
    Research Letter

    Gormally, M. V.; Chen, M. F.; Noronha, A. M.; Panageas, K.; Reynolds, M.; Kohlasch, K.; Novak, B.; Kee-Velez, T.; Clarke, N.; Eubank, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1C
    Journal Article

    O’Hara, M. H.; Jegede, O.; Dickson, M. A.; DeMichele, A. M.; Piekarz, R.; Gray, R. J.; Wang, V.; McShane, L. M.; Rubinstein, L. V.; Patton, D. R.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • International multicenter retrospective study from the Ultra-rare Sarcoma Working Group on low-grade fibromyxoid sarcoma, sclerosing epithelioid fibrosarcoma, and hybrid forms
    Journal Article

    Giani, C.; Salawu, A.; Ljevar, S.; Denu, R. A.; Napolitano, A.; Palmerini, E.; Connolly, E. A.; Ogura, K.; Wong, D. D.; Scanferla, R.; more...
    American Journal of Surgical Pathology (2025)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    D'Amato, G.; Wagner, A. J.; Ganjoo, K. N.; Stacchiotti, S.; Gelderblom, H.; Ryan, C. W.; Palmerini, E.; Ravi, V.; Saleh, R.; Le Cesne, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    Serrano, C.; Blay, J. Y.; Rutkowski, P.; Gelderblom, H.; Stacchiotti, S.; Falcon Gonzalez, A.; Desai, J.; Le Cesne, A.; Ferraresi, V.; Palmerini, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save